Charles River Laboratories International, Inc. (CRL)
| Market Cap | 20.45B |
| Revenue (ttm) | 3.04B |
| Net Income (ttm) | 375.07M |
| Shares Out | 49.98M |
| EPS (ttm) | 7.36 |
| PE Ratio | 55.54 |
| Forward PE | 41.49 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | August 3 |
| Last Price | $408.99 |
| Previous Close | $405.60 |
| Change ($) | 3.39 |
| Change (%) | 0.84% |
| Day's Open | 406.40 |
| Day's Range | 404.21 - 409.27 |
| Day's Volume | 153,598 |
| 52-Week Range | 197.33 - 410.52 |
Strong performance by the RMS, DSA and Manufacturing segments is driving the top line for Charles River (CRL).
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #2Q2021--Charles River Laboratories schedules second-quarter 2021 earnings release and conference call
Charles River (CRAI) has a diversified business with service offerings across areas of functional expertise, client base and geographical regions.
The stock price of Charles River Laboratories, a company that offers clinical laboratory, gene therapy, and cell therapy services for the pharmaceuticals industry, has seen a 13% rise over the last twe...
The consolidation between Charles River (CRL) and Vigene is set to establish an end-to-end, gene-modified cell therapy solution in the United States.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories completes acquisition of Vigene Biosciences.
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces long-term solar contract for North American operations, moves closer to goal of sourcing 100% renewable electricity by 2030.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #investorconference--Charles River Laboratories to present at June Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #investorday--Charles River Laboratories to Host Virtual Investor Day
Charles River (CRAI) welcomes Daniel Roffman to the position of vice president at its Forensic Services Practice.
Charles River (CRAI) continues to focus on generating balanced and profitable growth through optimum organic and inorganic means.
Contract researcher Charles River Laboratories International Inc (NYSE: CRL) will dole out $292.5 million for gene therapy CDMO Vigene Biosciences with the possibility for an additional $57.5 million in...
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories to acquire Vigene Biosciences, a premier cell and gene therapy CDMO providing viral vector-based gene delivery solutions
Charles River's (CRAI) first-quarter 2021 earnings and revenues improve year over year.
NEW YORK, May 10, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600: S&P MidCap 400 constituent Charles River Laboratories I...
Charles River Labs International saw its IBD SmartSelect Composite Rating jump to 96 Wednesday, up from 92 the day before. The post Charles River Labs International Joins Elite List Of Stocks With 95-Pl...
Charles River (CRL) delivered earnings and revenue surprises of 15.53% and 3.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Charles River (NYSE:CRL) decreased 0.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 37.50% year over year to $2.53, which beat the es...
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Announces First-Quarter 2021 Results
Medical stocks Medpace Holdings and Charles River Laboratories were making inroads toward profit-taking zones on Friday as Align Technology flirted with a breakout out of a cup base. The post Three Scor...
Corporate Executive VP & CFO of Charles River Laboratories International Inc (30-Year Financial, Insider Trades) David Ross Smith (insider trades) sold 2,000 shares of CRL on 04/15/2021 at an average pr...
Investment company Royce International Premier Fund (Current Portfolio) buys New Work SE, Learning Technologies Group PLC, NICE Information Service Co, discoverIE Group PLC, OBIC Business Consultants Co...
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Schedules First-Quarter 2021 Earnings Release and Conference Call
WILMINGTON, Mass. & MONTREAL--(BUSINESS WIRE)---- $CRL #Biopharma--Charles River and Valence Discovery announce strategic partnership to provide clients access to AI-enabled drug design.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories acquires Retrogenix
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #acquisition--Charles River Laboratories completes the acquisition of Cognate BioServices.
Clinical trial leaders PPD and Charles River Labs test resistance and new buy points. The post Clinical Trial Leaders PPD And CRL Stock Test New Buy Points appeared first on Investor's Business Daily.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories announced that it has closed its previously announced offering of $1 billion of senior notes
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #bondoffering--Charles River Laboratories prices $1 billion of senior notes
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #bondoffering--Charles River Laboratories announces planned offering of $1 billion of senior notes
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories to present at Barclays Global Healthcare Conference
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Today, Charles River announced a partnership with Kibur Medical to offer exclusive access to its IMD for in vivo preclincal oncology studies.
Charles River (CRL) delivered earnings and revenue surprises of 12.74% and 4.63%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories Announces Fourth-quarter and Full-year 2020 Results and Provides 2021 Guidance
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW), the drug repurposing company, said pre-clinical studies on the psychedelic compound DMT to treat stroke will be carried out at the Charles...
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
WILMINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River today announced that it has entered into a strategic partnership with Cypre, Inc. to expand in vitro testing services.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories schedules fourth-quarter 2020 earnings and 2021 guidance release and conference call.
WILMINGTON, Mass. & SHANGHAI--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announced that it has entered into a strategic partnership with JADE Biomedical to expand global biologics capabilities.
Increasingly, the Wall Street firms we cover are starting to agree that while the future for the U.S.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories to present at J.P. Morgan Healthcare Conference
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #acquisition--Charles River acquires Distributed Bio, a next-generation antibody discovery company, to establish a premier, large molecule discovery platform
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #earnings--Charles River Laboratories to present at upcoming conferences
Charles River reported Q3 2020 results that beat the top- and bottom-line estimates. Moreover, the company has beat analysts' earnings estimates in each of the last eight quarters. Charles River appears...
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.
About CRL
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services ... [Read more...]
| Industry Diagnostics & Research | IPO Date Jun 23, 2000 |
| CEO James Foster | Employees 18,400 |
| Stock Exchange NYSE | Ticker Symbol CRL |
Financial Performance
In 2020, CRL's revenue was $2.92 billion, an increase of 11.55% compared to the previous year's $2.62 billion. Earnings were $364.30 million, an increase of 44.55%.
Analyst Forecasts
According to 17 analysts, the average rating for CRL stock is "Buy." The 12-month stock price forecast is 377.75, which is a decrease of -7.64% from the latest price.